Biotech | October 22, 2021
WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Subscribe To Our Newsletter & Stay Updated
